Pilonidal AbscessMANAGEMENT

DERMATOLOGY PRESENTATIONS · 12 SECTIONS

⚲

613 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Allergic contact dermatitis Bullous Pemphigoid Cutaneous Abscess DRESS syndrome Eczema Herpeticum Erysipelas Erythema multiforme Henoch-Schönlein purpura Herpes Zoster (Shingles)Herpetic Whitlow Hidradenitis suppurativa Paronychia Pediculosis (Lice)Pemphigus Vulgaris Pilonidal Abscess Pressure injury Psoriasis (acute flare)Psoriasis Flare Staphylococcal Scalded Skin Syndrome Stevens-Johnson Syndrome (SJS)Toxic Epidermal Necrolysis (TEN)Urticaria (acute)Warfarin-induced Skin Necrosis

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp33

Immediate priorities

›Time-critical threats to recognize

›Sepsis or hemodynamic instability

›Temperature >38.3°C or <36°C with tachycardia HR >90

›SBP <90 mmHg or MAP <65 mmHg

›Lactate >=2 mmol/l

›Necrotizing soft tissue infection

›Rapidly expanding cellulitis beyond wound margins

›Crepitus on palpation

›Skin necrosis or blistering overlying abscess

›Pain out of proportion to visible findings

›If necrotizing infection suspected, emergent surgical consultation

›Do not delay for imaging if clinical suspicion high

›IV antibiotics immediately: vancomycin + piperacillin-tazobactam

Stabilization and monitoring

›Initial stabilization steps

›IV access with fluid resuscitation if septic

›30 ml/kg isotonic crystalloid bolus for septic shock

›Reassess after each bolus for fluid responsiveness

›Oxygen supplementation if SpO2 <94%

›Target SpO2 >=94%

›Blood cultures x2 before antibiotics if septic

›Wound culture from drainage

›Continuous cardiac monitoring and pulse oximetry

›Repeat vital signs q30 minutes while unstable

Consult triggers

›Surgical consultation indications

›Necrotizing soft tissue infection suspected

02History/hx55

Presenting symptoms

›Core symptom complex

›Sacrococcygeal pain

›Rapid onset over hours to days

›Throbbing quality worsened by sitting, walking, or pressure

›Purulent or serosanguinous drainage from natal cleft

›Foul-smelling discharge

›Spontaneous drainage

›Fever or chills

›Systemic involvement marker

›Sweats or rigors

Risk factors

›Predisposing patient characteristics

›Male sex

›Male-to-female ratio at least 2:1

›Young adulthood

›Peak incidence age 19-21 years

›Obesity

›BMI as independent risk factor

›Hirsutism and excessive body hair

›Hair follicle obstruction mechanism

›Sedentary lifestyle or prolonged sitting

›Truck drivers, office workers

›Long-distance driving

›Deep natal cleft anatomy

›Anatomic predisposition to hair accumulation

›Family history of pilonidal disease

›Increased incidence with positive family history

03Physical Exam/exam44

Vital signs and general

›Hemodynamic and systemic assessment

›Temperature

›Fever >38°C suggests systemic involvement

›Hypothermia as severe sepsis marker

›Heart rate

›Tachycardia HR >90 as SIRS criterion

›Blood pressure

›SBP <90 mmHg or MAP <65 mmHg triggers sepsis protocol

›General appearance

›Toxic-appearing patient flags systemic infection

Natal cleft inspection

›Characteristic findings

›Midline pits in natal cleft

›Pathognomonic for pilonidal disease

›Almost always present in true pilonidal abscess

›Erythema and induration

›Typically lateral and superior to midline

›Extent of surrounding cellulitis

›Fluctuance

›Abscess ready for drainage

›Point of maximal fluctuance for incision placement

›Active purulent or serosanguinous drainage

›Foul odor on inspection

›Secondary openings off-midline

›Granulation tissue at sinus openings

›Marker of chronic disease

04Differential Diagnosis/ddx40

Life-threatening mimics

›Necrotizing soft tissue infection

›ICD-10: M72.6

›Rapidly spreading with systemic toxicity

›Crepitus, skin necrosis, pain out of proportion

›CT may show gas in soft tissues

›Sepsis from skin and soft tissue source

›ICD-10: A41.9

›SIRS criteria with suspected infectious source

›Requires blood cultures and IV antibiotics

Common alternative diagnoses

›Perianal or anorectal abscess

›ICD-10: K61.0-K61.4

›More caudal location closer to anal verge

›No midline pits

›Distinct from pilonidal by location and origin

›Hidradenitis suppurativa

›ICD-10: L73.2

›Recurrent abscesses in apocrine gland-bearing areas

›Axillary, groin, and gluteal involvement

›Bilateral or multifocal pattern

›No midline pits; tunneling between lesions

›Infected furuncle or carbuncle

›ICD-10: L02.31

›No midline pits, no sinus tracts

›Staphylococcal folliculitis origin

Less common diagnoses

›Dermoid cyst

05Laboratory Tests/lt33

Routine labs

›Lab studies for uncomplicated abscess

›Routine labs generally unnecessary for uncomplicated pilonidal abscess

›Diagnosis is clinical

›Reserve labs for systemic illness or uncertainty

›Wound culture recommended when draining abscess

›Most common organism: Staphylococcus aureus including MRSA

›Mixed anaerobic flora also common

›Gram stain of purulent drainage

Systemic illness labs

›Labs indicated when SIRS or sepsis suspected

›Complete blood count with differential

›Leukocytosis >12 x10^9/L as SIRS criterion

›Leukopenia <4 x10^9/L also concerning

›Bandemia may indicate severe infection

›Basic metabolic panel

›Renal function before antibiotic dosing

›Electrolyte abnormalities with sepsis

›Lactate

›Lactate >=2 mmol/l defines sepsis with infection

›Lactate >=4 mmol/l defines septic shock

›Blood cultures x2

›Before antibiotic administration

›Yield increases with temperature >38.5°C or <36°C

›C-reactive protein

›Inflammatory marker for severity assessment

›Useful for monitoring treatment response

06Diagnostic Tests/dt52

Scoring Systems

›No validated scoring system specific to pilonidal abscess

›No universally accepted classification system exists

›No widely adopted severity scoring tool

›SIRS criteria used for systemic severity stratification

›Temperature >38°C or <36°C

›HR >90 beats/min

›RR >20 or PaCO2 <32 mmHg

›WBC >12 x10^9/L or <4 x10^9/L or bands >10%

›LRINEC score for necrotizing fasciitis risk

›Laboratory risk indicator for necrotizing fasciitis

›Score >=6 raises suspicion for necrotizing infection

›Score >=8 strongly predictive; sensitivity 59%, specificity 97%

MRI

›MRI indications for pilonidal disease

›Reserved for complex or recurrent disease

›Maps sinus tract extent

›Rules out deep extension to sacral fascia or bone

›Differentiates from perianal fistula

›MRI fistula protocol

›T2-weighted sequences delineate soft tissue tracts

›Distinguishes pilonidal from cryptoglandular fistula

›Identifies occult tracts not visible on surface exam

›MRI for suspected sacral osteomyelitis

›High sensitivity for bone marrow involvement

›Gadolinium enhancement for abscess vs. phlegmon

›CT indications for pilonidal disease

07Disposition/dispo36

Discharge criteria

›Criteria for ED discharge

›Uncomplicated abscess successfully drained

›No SIRS or sepsis criteria met

›Immunocompetent host

›Tolerating oral intake

›Adequate pain control achieved

›Reliable follow-up available

›Wound check in 48-72 hours arranged

›Surgical consultation within 2-4 weeks if recurrent disease

Admission criteria

›Indications for inpatient admission

›Sepsis or hemodynamic instability

›IV antibiotics and resuscitation required

›Necrotizing soft tissue infection

›Emergent operative debridement

›Failed outpatient management

›Incomplete drainage with worsening cellulitis

›Significant immunocompromise with complicated infection

›Diabetes with poor control, HIV, chemotherapy

›Large or complex abscess requiring OR drainage

›Not amenable to bedside I&D

Observation

›Criteria for ED observation or short stay

›Borderline SIRS with extensive surrounding cellulitis

›IV antibiotics with reassessment in 12-24 hours

›Inadequate pain control after drainage

›Monitoring before discharge

08Treatment/t103

Incision and drainage

›Definitive ED treatment

›Incision and drainage is the mainstay of acute management

›ASCRS Grade 1B strong recommendation

›50% of pilonidal disease patients present with acute infection

›Incision technique

›Incise over point of maximal fluctuance

›Place incision lateral to midline pits

›Express pus and break up loculations

›Remove hair and debris from cavity

›Unroofing with curettage technique

›Lay-open technique as single-step option

›Significantly reduces recurrence: 10% vs. 54% compared to simple I&D

›Improves healing at 10 weeks: 96% vs. 79%

›Performed under local anesthesia in ED

Analgesia for procedure

›Local anesthesia for I&D

›Local anesthetic infiltration

›Lidocaine 1% with epinephrine 1:100,000 for field block

›Maximum dose lidocaine with epi: 7 mg/kg

›Allow 3-5 minutes for onset

›Procedural sedation for extensive or deep abscess

›Ketamine 1-2 mg/kg IV for deep sedation

›Midazolam 0.02-0.05 mg/kg IV as adjunct

›Pre-procedure analgesia

›Oral or IV opioid for moderate-to-severe pain before procedure

›Non-opioid adjuncts: ketorolac 15-30 mg IV

Wound management

›Post-drainage wound care

›Wound packing

›Routine packing not recommended by contemporary evidence

›No outcome advantage with packing; increases pain

›Simple dressing changes preferred

›Wound healing expectation

›Heals by secondary intention

›4-10 weeks depending on cavity size

›Sitz baths for comfort and hygiene

›Twice daily after drainage

›Hair removal from wound and surrounding area

›Weekly shaving of gluteal cleft

›Laser epilation for long-term prevention

Antibiotics

›Antibiotic decision

›Antibiotics NOT routinely required after uncomplicated I&D

›ASCRS guidelines support drainage as mainstay

›NEJM NEJM-2017 trial: no benefit of antibiotics for smaller skin abscesses without SIRS

›Indications for antibiotics

›SIRS criteria met

›Significant surrounding cellulitis

›Immunocompromised host

›Failed initial treatment

›Outpatient antibiotic regimens for MRSA coverage

›TMP-SMX (trimethoprim-sulfamethoxazole)

›1 double-strength tablet (160/800 mg) orally twice daily

›Duration: 7-10 days

›Clindamycin

›300-450 mg orally three times daily

›Duration: 7-10 days

›Caution in patients with prior C. difficile history

›Amoxicillin-clavulanate if mixed flora suspected

›875/125 mg orally twice daily for 7-10 days

›Provides anaerobic coverage

›IV antibiotics for sepsis or necrotizing infection

›Vancomycin for MRSA coverage

›25-30 mg/kg IV loading dose

›Target AUC/MIC 400-600 mcg/ml per hour

›Piperacillin-tazobactam for broad gram-negative and anaerobic coverage

›3.375 g IV q6h or 4.5 g IV q8h

›Alternative: Meropenem 1 g IV q8h for severe or resistant infections

›Add vancomycin for MRSA coverage

Needle aspiration alternative

›Needle aspiration as ED alternative

›Emerging alternative to formal I&D

›Select non-septic, non-immunocompromised patients

›No skin necrosis present

›Technique

›18-gauge needle aspiration of purulent collection

›Add oral antibiotics covering aerobes and anaerobes

›Success rate

›95% success in converting to elective procedure in one prospective cohort

›Converts emergency to elective surgical setting

Definitive surgical options

›Elective surgical management discussion

›Simple excision with primary closure

›Higher recurrence with midline closure

›Off-midline closure techniques

›Karydakis flap procedure

›Bascom cleft lift

›Lower long-term recurrence than midline closure

›Cochrane 2024 review supports off-midline closure

›Minimally invasive options

›SiLaC: sinusectomy with laser-assisted closure

›EPSiT: endoscopic pilonidal sinus treatment

›International Society of Laser Proctology position paper 2025

Recurrence prevention

›Long-term recurrence prevention strategies

›Recurrence rate after simple I&D

›15-40% recurrence after simple incision and drainage

›Overall recurrence 0-66% across all treatments

›80% of recurrences occur within the first year

›Hygiene measures

›Regular cleaning of natal cleft with chlorhexidine washes

›Hair removal strategies

›Weekly shaving of gluteal cleft

›Laser epilation for sustained hair removal

›Weight management

›Obesity reduction as modifiable risk factor

›Behavioral modifications

›Avoid prolonged sitting

›Use cushions if sedentary occupation required

09Special Populations/sp51

Pregnancy

›Pilonidal abscess in pregnancy

›Incidence and presentation

›Pilonidal disease is uncommon during pregnancy

›Increased sacrococcygeal pressure may exacerbate symptoms

›Same clinical presentation as non-pregnant patients

›Procedural considerations

›Incision and drainage safe in pregnancy

›Lateral decubitus position preferred for procedure

›Local anesthesia with lidocaine considered safe in pregnancy

›Avoid epinephrine in large doses

›Antibiotic safety in pregnancy

›TMP-SMX: avoid in first trimester (folate antagonism) and near term (kernicterus risk)

›Clindamycin considered safe in pregnancy (Category B equivalent)

›Amoxicillin-clavulanate acceptable in pregnancy

›Consult obstetrics for systemic infection or uncertain drug choice

›Fetal monitoring considerations

›Fetal heart rate monitoring if gestational age >=24 weeks and sepsis present

Geriatric

›Pilonidal abscess in older adults

›Epidemiologic context

›Pilonidal disease predominantly affects young adults

›Rare presentation in elderly; consider alternative diagnoses

›Malignant degeneration more likely in elderly with chronic disease

›Atypical presentation

›Blunted fever response; normal temperature does not exclude infection

›Delirium may be only presenting sign of sepsis

›Baseline functional status important for surgical planning

10Background/b59

Epidemiology

›Incidence and demographics

›Pilonidal disease incidence approximately 26 per 100,000 persons per year

›Predominantly affects young adults age 15-30 years

›Peak incidence at age 19-21 years

›Sex distribution

›Male-to-female predominance at least 2:1

›Males have deeper natal clefts and more body hair

›50% of pilonidal disease patients present with acute abscess

›The other 50% present with chronic sinus or draining tract

›Recurrence burden

›Simple I&D recurrence rate 15-40%

›Overall recurrence across all treatments 0-66%

›Approximately 80% of recurrences within first year

›Risk factor prevalence

›Obesity a major modifiable risk factor

›Sedentary occupations strongly associated

›Family history increases risk and advances onset

Pathophysiology

›Acquired disease mechanism

›Not a congenital condition

›Acquired through hair follicle obstruction and foreign-body reaction

›Hair enters the skin from outside, not from within follicles

›Hair follicle obstruction

›Keratin debris obstructs follicle in natal cleft

›Folliculitis leads to abscess formation

›Hair shafts pierce skin and act as foreign body

›Foreign-body reaction

11Patient Discharge Instructions/pdi57

copy discharge instructions

›Wound care after drainage

›Keep wound clean and dry

›Gentle cleaning with mild soap and water twice daily

›Sitz baths twice daily for comfort and hygiene

›Dressing changes

›Simple gauze dressing over wound

›Change dressing daily or when saturated

›No packing required unless specifically instructed by your doctor

›Wound healing timeline

›Wound heals from inside out by secondary intention

›Healing takes 4-10 weeks depending on cavity size

›Some drainage and minor bleeding is normal early on

›Activity and lifestyle instructions

›Activity restrictions

›Avoid prolonged sitting for the first 1-2 weeks

›Avoid strenuous exercise until wound is healed

›Use a cushion or donut pillow if sitting required for work

›Hair removal

›Shave the area around the wound weekly

›This is one of the most important steps to prevent recurrence

›Hygiene

›Keep the natal cleft clean and dry

›Chlorhexidine wash to the area reduces bacteria

›Weight management

›Weight loss if overweight significantly reduces recurrence risk

›Medications

›Pain management

12References/r50

Guidelines and key sources

›ASCRS Clinical Practice Guidelines

›Johnson EK, Vogel JD, Cowan ML, Feingold DL, Steele SR

›The American Society of Colon and Rectal Surgeons' Clinical Practice Guidelines for the Management of Pilonidal Disease

›Diseases of the Colon and Rectum. 2019

›ASCRS Grade 1B recommendation for I&D as acute treatment

›Key recommendation: drainage alone adequate for uncomplicated abscess

›Antibiotics not routinely required post-I&D

›IDSA Skin and Soft Tissue Infection Guidelines

›Stevens DL, Bisno AL, Chambers HF, et al.

›Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update

›Clinical Infectious Diseases. 2014

›Antibiotic indications: SIRS, immunocompromise, cellulitis

›JAMA Surgery systematic review

›Gil LA, Deans KJ, Minneci PC

›Management of Pilonidal Disease: A Review

›JAMA Surgery. 2023

›Comprehensive review of epidemiology, treatment options, and recurrence

Landmark trials

›Antibiotic evidence for skin abscesses

›Daum RS, Miller LG, Immergluck L, et al.

›A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses

›New England Journal of Medicine. 2017

›TMP-SMX reduces treatment failure for skin abscesses including pilonidal

›Needle aspiration alternative

›Hussain ZI, Aghahoseini A, Alexander D

›Converting Emergency Pilonidal Abscess Into an Elective Procedure

›Diseases of the Colon and Rectum. 2012

Learn More: Pilonidal Abscess→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.